Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0017638 (glioma)
 30,880 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A 32-year-old man developed an intracranial glioblastoma multiforme 10 years after irradiation for an incompletely resected convexity meningioma. The association of these two tumors is exceedingly rare. Therefore, we propose that this is a case of radiation-induced glioma and review the evidence supporting this view.
 ...
PMID:Glioblastoma occurring after radiation therapy for meningioma: case report and review of literature. 301 23

The Neuro-oncology Service of the University of California Brain Tumor Research Center conducted a nonrandomized phase II study to evaluate, in patients with recurrent malignant glioma, the benefit of a four-drug combination (BFHM) consisting of carmustine (1,3-bis (2-chloroethyl)-1-nitrosourea), 5-fluorouracil, hydroxyurea, and 6-mercaptopurine. There were 29 evaluable glioblastoma multiforme patients and 45 nonglioblastoma anaplastic glioma patients available for analysis. Tumor progression was analyzed as the primary study endpoint. Of the glioblastoma patients, 16 of 29 (55%) responded or stabilized on therapy; of the other anaplastic gliomas, 32 of 45 (71%) responded or stabilized. For patients who stabilized or responded to treatment, BFHM achieved a median time to tumor progression of 46 weeks with a 25th percentile time to tumor progression of 68 weeks for anaplastic gliomas and a median time to tumor progression of 23 weeks with a 25th percentile time to tumor progression of 36 weeks for glioblastoma multiforme patients. A Cox multivariate analysis demonstrated that age and Karnofsky score were important prognostic variables for these patients.
 ...
PMID:Phase II study of combined carmustine, 5-fluorouracil, hydroxyurea, and 6-mercaptopurine (BFHM) for the treatment of malignant gliomas. 302 25

To determine the percentage of patients who developed multiple central nervous system (CNS) gliomas during postoperative radiation therapy and chemotherapy, the authors reviewed the records of 1047 patients treated between December 2, 1976, and August 16, 1985, who had an original diagnosis of supratentorial glioblastoma multiforme or other anaplastic glioma. The occurrence of multiple lesions was verified by neurodiagnostic studies (computerized tomography or myelography) or by findings at operation or autopsy. Twelve patients (1.1%) who presented with multiple lesions were excluded from this analysis. There were 405 patients with glioblastoma multiforme; their median age was 46.5 years (range 22 to 70 years). Eighteen (5%) of these patients had multiple CNS lesions, five of which were in the spinal cord. The median time from diagnosis to detection of the second lesion in this group was 59.5 weeks (range 10 to 182 weeks). There were 630 patients with anaplastic glioma (which included mixed malignant glioma and highly anaplastic, gemistocytic, moderately anaplastic, and anaplastic astrocytomas); their median age was 30 years (range 2 to 62 years). Fifty-four (8.6%) of these patients had multiple lesions, 10 of which were in the spinal cord; only one case of extraneural metastasis was found. The median time from diagnosis to detection of the second lesion in this group was 101 weeks (range 14 to 459 weeks). These results show that more than 90% of CNS gliomas recur at the site of the original tumor. Considering the high frequency of intellectual dysfunction after whole-brain radiation therapy, the use of focal radiation fields appears to be the most judicious approach to the treatment of patients with gliomas.
 ...
PMID:Development of multiple lesions during radiation therapy and chemotherapy in patients with gliomas. 302 31

The expression of class II major histocompatibility (MHC) antigens is central to the mounting of a successful immune response. Understanding the molecular mechanisms involved in the induction of class II MHC expression may therefore provide the knowledge necessary to manipulate the immune system appropriately. We are particularly interested in the induction of class II MHC antigens on cells in the brain, because of the potential involvement of such brain cells in the initiation and perpetuation of autoimmune-like diseases of the central nervous system. We examined the mechanisms involved in interferon-gamma (IFN-gamma) induction of class II MHC antigens on a human glioblastoma multiforme cell line. This paper describes the identification of a 297-bp (base pair) fragment of the class II MHC DR alpha chain gene which is involved in IFN-gamma induction. We were able to identify this IFN-gamma responsive sequence by preparing recombinant plasmids containing 5' flanking pieces of the human DR alpha chain gene placed upstream of the indicator gene, chloramphenicol acetyltransferase (CAT). These recombinant plasmids were transfected into human glioma cells which were then cultured in the presence or absence of IFN-gamma. After 48 hr, transient expression of CAT was assayed by thin layer chromatography. CAT enzyme activity was significantly increased only in IFN-gamma-treated cells. This increase was also reflected at the RNA level in that IFN-gamma treatment resulted in higher CAT transcripts. A computer homology search revealed a possible consensus sequence shared among different IFN-gamma-inducible genes.
 ...
PMID:Identification of an interferon-gamma response region 5' of the human histocompatibility leukocyte antigen DR alpha chain gene which is active in human glioblastoma multiforme lines. 302 77

Three patients developed the sudden onset of total blindness several months after treatment with oral CCNU and low-dose whole-brain radiation. The anterior visual system was included in the radiation field in all patients. Radiotherapy was given for a frontal-lobe glioblastoma multiforme, for central nervous system prophylaxis in a patient with oat cell carcinoma of the lung, and for a parietal-lobe glioblastoma multiforme. None of the neoplasms involved the anterior visual system. The radiation dose ranged from 3000 to 4650 rad and the oral CCNU dosage from 300 mg to 1050 mg. Patients 1 and 2 also received other chemotherapeutic agents. Patient 3 who was treated only with oral CCNU and cranial irradiation died. At autopsy the brain showed a widely infiltrating residual high-grade glioma as well as patchy coagulative necrosis with swollen axons and dystrophic calcifications. The optic chiasm showed severe demyelination, axonal loss, and hyalinized vessels. Synergism between oral CCNU and radiation may account for the blindness produced.
 ...
PMID:Sudden onset of blindness in patients treated with oral CCNU and low-dose cranial irradiation. 302 94

Histologic sections from 71 patients with glioblastoma multiforme were reviewed to identify histologic prognostic factors and to explain the significantly shorter survival in older patients. Slides were studied for 14 histologic variables from a group of 35 patients aged less 45 years and from 36 patients aged 65 years or more. The relation of these histologic factors to the length of survival and age group was then investigated. The results document the marked histologic and cytologic heterogeneity of the glioblastoma and reaffirm the importance of necrosis as a prognostic factor. The results further suggest that patients whose glioblastomas contained microcysts, pseudopalisading, cells with astrocytic differentiation, and large areas of better differentiated glioma, did better than those patients whose lesions were homogeneously composed of small cells or whose lesion had a small median nuclear size. The study reaffirmed the strong (P less than 0.0001) negative relationship between advancing age and duration of postoperative survival. The presence of necrosis, a smaller standard deviation of nuclear size, the extent of vascular proliferation, the absence of well differentiated neoplastic fibrillary astrocytes, and neoplasms composed homogeneously of small cells were related to patient age and offered a possible explanation for at least part of the observed age effect. However, the strong relation between age and survival remained significant when adjusted for other variables, and the effect of age must rest largely on factors other than those detected in this morphologic study.
 ...
PMID:Patient age, histologic features, and length of survival in patients with glioblastoma multiforme. 303 May 31

Precise localization of alkaline phosphatase (ALPase) activity in human gliomas was examined by light and electron microscopy in association with malignant transformation, paying much attention to changes in blood-brain barrier. Materials used were eight cases of gliomas four of which were astrocytoma grade 2, one astrocytoma grade 3, and three, glioblastoma multiforme, respectively. Specimens were quickly fixed in cacodylate-buffered 2% glutaraldehyde at 4 degrees C for 1 hour and rinsed overnight in the same buffer. Frozen or nonfrozen sections (40 microns thick) were made and incubated at 20 degrees C for 40 min, and processed for light and electron microscopy. For the demonstration of ALPase activity, the lead citrate method (Mayahara et al., 1967) was employed. By light microscopy, ALPase activity appeared to be mainly restricted to the capillary wall. By electron microscopy, reaction product representing ALPase activity was distributed in the plasma membrane of endothelial cells both in astrocytomas and in glioblastoma. In astrocytoma grade 2, activity was primarily localized along the abluminal surface of endothelial cells. In glioblastoma, on the other hand, ALPase activity was positive on the luminal surface of the plasma membrane of endothelial cells. It was much more intense than that along the abluminal surface. Regional differences in enzyme cytochemistry may represent functional heterogeneity in the endothelial cell membrane. In brain tumors, changes in distribution pattern of enzyme activity were visualized in the present study in association with glioma malignancy. This might represent a functional aspect of changes in blood-brain barrier in human glioma tissue during course of its malignant transformation.
 ...
PMID:[Alkaline phosphatase activity in human gliomas as revealed by light and electron microscopy]. 304 56

Eflornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase, and mitoguazone (MGBG), a competitive inhibitor of S-adenosylmethionine decarboxylase, were evaluated in a phase I-II study for patients with primary recurrent malignant brain tumors. All patients had failed prior radiation therapy and most had also failed prior chemotherapy. Two dose schedules were used, with the second schedule (Group II) a modification of the first schedule (Group I). The Group II schedule, with different dose levels, was better tolerated than the Group I schedule. Gastrointestinal and myelotoxicity were dose-limiting in most patients, and tinnitus was dose-limiting in two patients. Nineteen of 33 evaluable patients had anaplastic gliomas, in whom response was observed in 21%, stable disease in 53%, and immediate progression after one course of therapy in 26%. Of six patients with glioblastoma multiforme, two had brief stabilization of disease. An additional patient with brainstem glioma and ependymoma also had disease stabilization. Four patients with medulloblastoma, a spinal cord mixed glioma, and one with oligodendroglioma failed DFMO-MGBG. Based on this study, we believe that a combination of DFMO and MGBG is well-tolerated and deserves further evaluation for patients with anaplastic gliomas, particularly those that appear to be biologically slow growing.
 ...
PMID:Phase I-II study of eflornithine and mitoguazone combined in the treatment of recurrent primary brain tumors. 310 81

In a group of 139 patients with poorly differentiated brain gliomas controlled clinical trial was carried out for assessment of two methods of postoperative treatment. After possibly radical removal of the glioma the patients were treated by radiotherapy with 60Co teletherapy in doses of 60 Gy (30 fr) in depth during 6 weeks, and randomly chosen patients received also CCNU in one dose of 100 mg/m repeated at intervals of 6-8 weeks. The administration of CCNU failed to improve the therapeutic results. The median survival time in the whole group was 49 weeks. The survival rate after 1, 2 and 3 years was 45.4%, 22.8% and 14.9% respectively. The survival times of cases of glioblastoma multiforme were not significantly different from those of patients with other poorly differentiated gliomas independently of the treatment method. The complications were not troublesome.
 ...
PMID:[Analysis of the results of combined treatment of poorly differentiated brain gliomas]. 322 60

A microencapsulation of living tumor cells by an improved membrane and droplet forming technique was established in our laboratory. This semipermeable microencapsulating membrane was impermeable to serum albumins (M.W. 66,000 or 45,000) and human hemoglobin (M.W. 64,000), but permitted passage of low molecular weight substances (alpha-Lactalbumin, or Trypsinogen; M.W. 14,200 or 24,000). The in vivo results showed that microencapsulated tumor cell lines (KB, human oral epidermoid cell; P-388 lymphocytic leukemia; GBM 8401/TSGH, glioma) and human colorectal carcinoma cells grew and proliferated exponentially within twenty days. The in vivo growth exhibited better than that in vitro. Histological and morphological findings of these four different kinds of tumor cells are similar to those of original tumor cells. Treatment of the microencapsulated tumor cells (MTC) with cytotoxic drugs (adriamycin, 5-fluorouracil and cyclophosphamide) in vitro showed no significant difference in percent inhibition (p greater than 0.05) between the encapsulated and non-encapsulated cells. The in vivo data indicated that different anti-cancer drugs had different inhibition effects. The results showed that the MTC model was useful for screening an appropriate cytotoxic drug and could be applied to clinical medicine in the near future.
 ...
PMID:Microencapsulation [corrected] of tumor cells and assay for selecting anticancer drugs. 324 21


<< Previous 1 2 3 4 5 6 7 8 9 10